Clinical Trial

DAratumumab and REvlimid REfractory MM

Name: DAratumumab and REvlimid REfractory MM — clinical trial record (NCT06541860)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

Retrospective and prospective multicenter observational study on patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with onlabel regimens.

Trial Details

NCT Number	NCT06541860
Lead Sponsor	Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions	Multiple Myeloma
Enrollment	100 participants
Start Date	2023-08-21
Primary Completion	2028-02-21 (estimated)
Study Completion	2028-08-21 (estimated)
Updated on ClinicalTrials.gov	2024-08-07